A detailed history of Allworth Financial LP transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Allworth Financial LP holds 1,527 shares of ALLO stock, worth $3,466. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,527
Previous 818 86.67%
Holding current value
$3,466
Previous $1,000 300.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

BUY
$2.08 - $3.5 $1,474 - $2,481
709 Added 86.67%
1,527 $4,000
Q2 2024

Jul 23, 2024

BUY
$2.23 - $4.38 $1,065 - $2,093
478 Added 140.59%
818 $1,000
Q4 2023

Jan 24, 2024

SELL
$2.28 - $3.5 $1,146 - $1,760
-503 Reduced 59.67%
340 $1,000
Q3 2023

Oct 31, 2023

BUY
$3.17 - $5.96 $2,482 - $4,666
783 Added 1305.0%
843 $2,000
Q2 2023

Jul 18, 2023

BUY
$4.53 - $6.74 $271 - $404
60 New
60 $0
Q3 2022

Oct 18, 2022

BUY
$10.32 - $17.28 $381 - $639
37 New
37 $0

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Allworth Financial LP Portfolio

Follow Allworth Financial LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Allworth Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Allworth Financial LP with notifications on news.